Journal of Young Pharmacists - Vol 10, Issue 2, Apr-Jun, 2018

Journal of Young Pharmacists - An official journal of InPharm Association is now fully funded and maintained by Phcog.Net. Journal of Young Pharmacists is an official Quarterly Journal funded by Phcog.Net. J Young Pharm is a peer-reviewed open-access Quarterly journal featuring research articles of exceptional significance in all areas of Pharmaceutical sciences. J Young Pharm provides comprehensive coverage of issues affecting Pharmaceutical education and Career.

Editor-in-Chief: Dr. S Parasuraman, Ph.D
ISSN: [ISSN: Print -0975-1483, Online - 0975-1505]
Frequency: Quarterly (4 issues/year)

We are delighted to announce that the Journal of Young Pharmacists (JYP) has been selected for coverage in this new Thomson Reuters Index.

The Journal of Young Pharmacists is pleased to announce that it has been accepted for indexing in the Emerging Sources Citation Index (ESCI), a new edition of Web of Science™. Content in this index is under consideration by Thomson Reuters to be accepted in the Science Citation Index Expanded™, the Social Sciences Citation Index®, and the Arts & Humanities Citation Index®. The quality and depth of content Web of Science offers to researchers, authors, publishers, and institutions sets it apart from other research databases.

Manuscripts can be submitted via Online through JOW

http://journalonweb.com/jyp

Contents inside

Editorial

- Green Chemistry – An Environmentally Benign Chemistry
  Authors: Ravichandran, Dr. V
  DOI: 10.5530/jyp.2018.10.30

Review Article

- Phase Diagrams for Three Component Mixtures in Pharmaceuticals and its Applications
  Authors: Dhoot, Abhishek Sunil, Naha Anup, Priya Jahu, and Xalxo Neha
  DOI: 10.5530/jyp.2018.10.31

- Warning Signs and Symptoms of Oral Cancer and its Differential Diagnosis
  Authors: Muthu, Kayitha, Vaishnavi Vedam, and G Sivadas
  DOI: 10.5530/jyp.2018.10.32

- Chitinases as Antibacterial Proteins: A Systematic Review
  Authors: de Medeiros, Mac Suelen Carneiro, Júnior José Edvar Monteiro, Sales Msc Gleiton Weyne Passos, Grangiro Thalles Barbosa, and Nogueira Nâdia Adjioy Pinto
  DOI: 10.5530/jyp.2018.10.33

Original Article

- Nebivolol: An Appealing, Awaited and Nitric Oxide Potentiator Drug for the Treatment of Heart Failure

http://www.joungpharm.org/v10/i2
Authors: Saini, Aryendra Kumar, Wal Pranay, Verma Manisha, Chandra Suresh, Singh Anurag, Yadav Sanjeev, Bansode Himanshu, Nischaya Kumar, and Saraswat Nikita
DOI: 10.5530/jyp.2018.10.34

Nephroprotective Effect of Anethum Graveolens in a Murine Model of Gentamicin Induced Nephrotoxicity
Authors: Srivastava, Pragati, R Rashmi Rao, Shenoy Preethi L, Manjrekar Poornima Ajay, Teerthank S., and S Bhuvaneswari
DOI: 10.5530/jyp.2018.10.35

Phytochemical Analysis, Antioxidant Properties and Brine Shrimp Lethality of Unripe Fruits of Solanum viarum
Authors: Braguinti, Wellington Luciano, Pires Natalia Valendolf, and Alves Bruno Bianchin
DOI: 10.5530/jyp.2018.10.36

Evaluation of the Antiungal Effect Vitis vinifera Extract on Candida albicans
Authors: Gadela, Leandro Maciel Uchoa, Valadas Lidia Audrey Rocha, de Fiallos Nicole Mello, and Peralta Sônia Luque
DOI: 10.5530/jyp.2018.10.37

Inhibition of HIV-1 Reverse Transcriptase of Selected Indonesia Medicinal Plants and Isolation of the Inhibitor from Erythrina variegata L. Leaves
Authors: Wardani, Alvi Kusuma, Mun'im Abdul, and Yanuar Ary
DOI: 10.5530/jyp.2018.10.38

Analysis of Novel C-X-C Chemokine Receptor Type 4 (CXCR4) Inhibitors from Hexane Extract of Euclea crispa (Thunb.) Leaves by Chemical Fingerprint Identification and Molecular Docking Analysis
Authors: Palansamy, Chella Perumal, and Ashafa Anofi Omotayo Tom
DOI: 10.5530/jyp.2018.10.39

Molecular Modeling and Docking Assessment of Thymic Stromal Lymphopoietin for the Development of Natural Anti Allergic Drugs
Authors: Adamu, Rahma Muhammad, and Malik B. K.
DOI: 10.5530/jyp.2018.10.40

FOXP3 Modulation of Quercetin-3-O-rhamnoside and its Impacts on Lupus Nephritis Mice
Authors: Indriyanti, Niken, Soerojo Joewono, and Khotib Junaidi
DOI: 10.5530/jyp.2018.10.41

Ethnomedicinal Plants Used for the Treatment of Malaria in Malaka, West Timor
Authors: Taek, Maximus M., EW Bambhang Prajogo, and Agil Mangestuti
DOI: 10.5530/jyp.2018.10.42

Antioxidant and Endotheliotropic Properties 4-Hydroxy-3, 5-Di-Tret-Butyl Cinnamic Acid under Conditions of Experimental Brain Ischemia
Authors: DI. Pozdvaykov, AV Voronkov, DS Zoletych, and AV Arti
DOI: 10.5530/jyp.2018.10.43

Effect of Nadi Shuddhi Pranayama, Kati Chakrasana and Vakrasana on Depression and Glycemic Control in Type 2 Diabetes Mellitus
Authors: D. Raja, Raju Deepthi Merin, TH Indu, KJ Suthy, C Jayakumar, and SPonnusankar
DOI: 10.5530/jyp.2018.10.44

Evaluation of Predisposing Factors Associated with Suspected Adverse Drug Reactions of Hospitalized Patients
Authors: Mudugubba, Manoj K., Raja Shekarachari Yogananda, and Dalway Saurabh
DOI: 10.5530/jyp.2018.10.45

Impact of Intensified Pharmaceutical Interventions in Medication Adherence in Chronic Kidney Disease Patients
Authors: Chandru, Dilip, Ganea VM, Sreekumar Sreelekha, Pradeep Anuja, Geogi Asha Susan, George Athira Elezbath, and Vipinachandran Ashira
DOI: 10.5530/jyp.2018.10.46

Pattern of Adverse Drug Reactions Reported with Use of Antimicrobial Drugs in a Tertiary Care Hospital
Authors: Prin, Shradhha Milind, Bungre Shreyas Ramchandra, Shinde Amar Dinkar, and Ramand Sunita Jaiprakash
DOI: 10.5530/jyp.2018.10.47

Incidence of Early Related-Complications of Port-A Catheter and Impact of Clinical Pharmacist Participation and Counselling Outcomes
Authors: Al-Taie, Amnar, and Koseçli Aygün
DOI: 10.5530/jyp.2018.10.48

The Effect of Pregabalin on the Quality of Life in Patients with Central Post-Stroke Pain
Authors: Rahijeg, Banuganarat, Kanati Zulfes, Andayani Tri Murti, and Dwipratasto Iwan
DOI: 10.5530/jyp.2018.10.49

Assessment of Therapeutic Outcome and Medication Adherence in Diabetes Consumed Insulin, Oral Hypoglycemics and Poly Herbal Drugs
Authors: Kardickiyan, Krishnan, Pannerselvam Perumal, Abhilash Thomas, Kameswaran Ramalingam, Krishnaveni Kandaswamy, and Srinivasan Sivamani
DOI: 10.5530/jyp.2018.10.50

Essential Medication Prescription and Associated Maternal Characteristic among Hospitalized Pregnant Women: A Retrospective Population Based Study
Authors: Basutkar, Roopa Satyanarayan, D Raja, P Divya, Das Sangram, and S Ponnusankar
DOI: 10.5530/jyp.2018.10.51

Short Communication

Analysis of Potential Drug Interactions in Brazilian Mental Health Services: Prevalence and Associated Factors
Authors: Silva, Sarah Nascimento, Lima Marina Guimarães, and Raas Cristina Mariano
DOI: 10.5530/jyp.2018.10.52
Foxp3 Modulation of Quercetin-3-O-rhamnose and Its Impacts on Lupus Nephritis Mice

Niken Indriyanti1, Joewono Soeroso2, Junaidi Khotib3
1Department of Pharmacology, Faculty of Pharmacy, Mulawarman University, Samarinda, East Kalimantan, INDONESIA.
2Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Jl. Prof. Dr. Moestopo, Surabaya, East Java, INDONESIA.
3Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga, J. Djarmawangsa Dalam, Surabaya, East Java, INDONESIA.

ABSTRACT
Background: Quercetin-3-O-rhamnose (QUE) has anti-inflammatory and anti-oxidative effects which probably beneficially used in lupus. Objective: This research was focused on analyzing the effects of QUE on Foxp3 modulation to result in an anti-inflammatory outcome in the kidney of severe lupus mice. Methods: This research used Pristane-induced female BALB/c lupus mice, and the biomarkers involved in were CD4+CD25+ T reg cells, Foxp3 T cells, anti-Sm, IL-6, and histopathology assessment of the kidney of lupus mice. The QUE group was treated and compared to the negative control which received placebo, and the positive control which received cyclophosphamide. Results: QUE increased the number of CD4+CD25+ T reg cells (negative control: 3.01 ± 3.43%; QUE: 18.77 ± 5.12%; positive control: 3.26 ± 1.09%), and Foxp3 significantly (p < 0.05) (negative control: 1.14 ± 0.54%; QUE: 2.00 ± 1.45%; positive control: 1.73 ± 1.14%). The anti-Sm level did not decrease, meanwhile the IL-6 decreased significantly, and the histopathological assessment of the kidney revealed the reducing effects of QUE on glomeruli. Conclusion: QUE has an anti-inflammatory activity which reduces the severity of lupus nephritis signs in lupus mice by initially increasing the CD4+CD25+ and Foxp3+ Tregs numbers. QUE is potential to be further developed as a safe treatment choice for lupus nephritis.

Key words: Glomerulonephritis, IL-6, Lupus, Pristane, T reg.

Key message: The efficacy of QUE as a safe drug on lupus mice was proven dominantly by modulating the CD4+CD25+Foxp3+ Tregs, so that the IL-6 and the glomerulonephritis decreased significantly.

Correspondence
Niken Indriyanti, Faculty of Pharmacy, Mulawarman University, Penajam Road, Gunung Keluak College of Mulawarman University, East Kalimantan Province, INDONESIA.
Phone: +62541 739491
Email: niken@farmasi.unmul.ac.id
DOI: 10.55530/jyp.2018.10.41

INTRODUCTION
Quercetin is a single compound that was expected to be effective to treat severe lupus manifestations because of its well-known anti-inflammatory 1 and anti-oxidative effects.2 This compound is predicted as an active marker of many medicinal plants which are examined as more safe, useful, and promising for lupus than the current treatments. Quercetin is also suppressing the manifestations of rheumatoid arthritis, a kind of autoimmune disease in rat model induced by using Complete Freund’s Adjuvant (CFA) and collagen. However, there is no data about the effect of quercetin on lupus.

In this research, we challenged quercetin in the form of its O-glycoside, named quercetin-3-O-rhamnose (QUE) to determine its efficacy on lupus mice induced by using Pristane. The O-glycoside form was chosen because it has a better solubility than its aglycone,3,4 so the QUE will be absorbed better. The QUE better absorption profile supports the advantage of QUE which has lower side effects in usual dose and in a long-term lupus treatment, compared to the current treatments. However, the effect of QUE needs to be analyzed by a series of lupus biomarkers. In this case, aligned to its anti-inflammatory effect, we chose the T cell-dependent pathway of lupus pathogenesis which consists of Tregs (CD4+CD25+ T cells and Foxp3+ T cells), anti-Smith (anti-Sm) antibody, IL-6, and the histopathology assessment of the kidney of lupus mice. Lupus mice which induced by using Pristane is an appropriate lupus model which reveals severe lupus signs as human lupus.5 Therefore, this study aimed to determine the QUE effects on T cell-dependent pathway biomarkers of lupus pathogenesis on lupus nephritis mice, which focused on Foxp3 modulation at the initial phase.

MATERIALS AND METHODS
Materials
Quercetin-3-O-rhamnose (QUE) was obtained from a Sigma-Aldrich distributor in Singapore. The female BALB/c mice aged four weeks which were stated as Species Pathogen Free (SPF) were purchased from the animal breeding of LPPT Unit 4, Gadjah Mada University, and then housed in animal laboratory of Faculty of Pharmacy, Universitas Airlangga under standard conditions. Pristane, a chemical to induce lupus mice was obtained from Sigma Aldrich. Anti-CD4, anti-CD25, anti-FoxP3, and anti-IL-6 were purchased from Biogenesis USA via Laboratory of Molecular Biology, Brawijaya University. Anti-Sm ELISA kit for mice was obtained from Cusabio. The chemicals used for hematoxylin-eosin staining was provided by the Laboratory of Veterinary Medicine, Universitas Airlangga.

Methods
Thirty female BALB/c mice with severe lupus nephritis signs (which previously injected by using Pristane) were calculated by considering the standard of deviation of our previous study.6 They were randomized and divided into three experimental groups that consist of 10 mice per group: a negative control group which received placebo, a QUE group which received quercetin-3-O-rhamnose at a dose of 21 mg/kg BW7, and a positive control group which received cyclophosphamide at a dose of 1 mg/kg BW. In fact, cyclophosphamide is used as an off-label drug for lupus. It has a probable nephrotoxic side effect, so that we used other reference. We tested three healthy mice as a comparison only for kidney tissue parameter, but not included in the experimental group.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
The treatments lasted for 21 days. At the end of the experiment, we performed an intra-cardiac injection to take the maximum volume of whole blood of each mouse. The serum of each mouse was used to examine the anti-Sm and 8-OHdG level by using ELISA kits. Then, the mice were sacrificed by cutting their aorta. The mice spleens and bone marrow were suddenly prepared and analyzed as the flow cytometry samples in the phosphate buffer saline (PBS). The fluorescence staining was done by using phycoer in (PE). Finally, the kidneys and the joints were isolated and then prepared well to become 4-6 μm thickness of histological specimens for hematoxylin-eosin (HE) staining. The microscopic observation of the kidney was done by using a light microscope (Nikon Eclipse Ci) at a magnitude of 400x, and then the joint inspection was done by using Optiplab microscope at a magnitude of 40x. The histopathology assessment was done by performing semi-quantitative analysis by following Moran’s method (kidney assessment). All the data were analyzed by facilitating of SPSS statistics. The ethical clearance of this research was certified by an ICUC of Faculty of Veterinary Medicine, Universitas Airlangga with the number of 512-KE.

RESULTS

The female BALB/c mice used in all experimental groups of this study were severe lupus mice which indicated by the high protein level in the urine (≥100 mg/dL). Their body weights were 20-35 g before the treatments started. We randomized the three groups based on body weight, so that we obtain the homogenous baseline between experimental groups.

QUE has high anti-inflammatory and antioxidant activities. Its anti-inflammatory effect correlates to T regulatory (T reg) cells. A T reg which plays a crucial role in repairing autoimmune condition is CD4+CD25+ T reg cells (Figure 1). QUE increase the relative percentage of CD4+CD25+ T reg cells significantly (p < 0.05). It means that the higher CD4+CD25+ T cells will maintain the balance of immune responses in lupus mice and predicted to reduce the systemic inflammation in severe lupus. However, this activity was further validated by a T cell-specific biomarker, FOXP3 to avoid a false positive data. The FOXP3 relative percentage in the QUE group increased significantly (p < 0.05) (Table 1), reveals the better immune response controlling activity. Quercetin has a high activity of anti-inflammatory effect. The increase of T reg in this result reveals the inflammatory controlling effect and the regulation of lupus auto-reactive T cells, so that the inflammatory manifestations in lupus mice can be decreased. The lupus-inflammatory manifestations will decrease if T regs have its usual number and function. Inflammation in lupus is a result of immune complexes which consist of auto-antigens and auto-antibodies. There are a wide variety of lupus-specific antibodies. A lupus drug candidate is highly potential if it reduces anti-Smith (anti-Sm) antibody, which is the main antibody that affects the tyrosine kinase. Therefore, anti-Sm trigs the production of a lot of lupus-specific antibodies. In this study, we measured the anti-Sm level (Table 2) in the blood of each lupus mice. QUE did not reduce the anti-Sm level significantly. It indicates that the target site or the heat of QUE is dominantly in anti-inflammatory activity, not in immunosuppressive activity. This is also a limitation of the use of anti-Sm as an antibody biomarker of lupus which is not as specific as anti-dsDNA since anti-Sm is a general trigger for some lupus antibodies. However, anti-dsDNA measurement in this model is not a good choice because no more than 40% of all induced mice produce anti-dsDNA, but more than 80% of them have high concentration of anti-Sm. However, this result will be supported by the further research about the effect of QUE on some lupus-specific antibodies, such as anti-dsDNA, anti-histone, and anti-nucleosome.

In this study, the anti-inflammatory activity of QUE was measured by analyzing a pro-inflammatory cytokine, IL-6 (Table 3). The total IL-6 significantly decreased (p < 0.05). It indicates the lower signs of systemic inflammation in the QUE groups compared to others. The lowering inflammation sign effect was directly observed in the kidney, the most influenced organ in severe lupus (Figure 2). In this case, the cyclophosphamide cannot be a golden standard since the nephrotoxicity side effect (11). Therefore, the normal mice were used as the normal standard for this microscopic observation in the kidney assessment. QUE reduces the inflamed glomerulus by reducing some histopathology indicators (Figure 2). The inflammatory cells deposit in the glomerulus of QUE group seems lower than the negative control group. The mesangial tissue thickness did not decrease, but the Bowman’s capsules look wider than the negative control group. These signs are beneficial to normalize the renal function in severe lupus mice. Beside glomerulus,

![Figure 1: Profile of percentage of CD4+CD25+ T cells of the negative control group (n=10) (a), QUE (n=10) (b), and the positive control (cyclophosphamide) group (n=10) (c) which measured from the mouse spleen cells by using PE staining, by facilitating of a flow cytometer BD FACS Calibur and BD CellQuest program.](image)

Table 1: Profile of the relative percentage of FOXP3+ T cells which was measured in the mice spleen cells of the three experimental groups by using PE staining in flow cytometer BD FACS Calibur which was supported by BD CellQuest program (n=10).

<table>
<thead>
<tr>
<th>Groups</th>
<th>FOXP3+ T cells ± SD (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>1.14 ± 0.54</td>
</tr>
<tr>
<td>QUE</td>
<td>2.00 ± 1.45*</td>
</tr>
<tr>
<td>Positive control</td>
<td>1.73 ± 1.14</td>
</tr>
</tbody>
</table>

*Significantly different to the negative control group (p < 0.05) using One-way ANOVA calculation in SPSS Statistics

Table 2: The anti-Sm level in the blood of three tested groups after the treatment period (n=10).

<table>
<thead>
<tr>
<th>Groups</th>
<th>Anti-Sm level (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>109.93 ± 12.02</td>
</tr>
<tr>
<td>QUE</td>
<td>105.67 ± 10.30</td>
</tr>
<tr>
<td>Positive control</td>
<td>100.74 ± 8.95</td>
</tr>
</tbody>
</table>

The analysis result is not significantly different to the negative control group (p < 0.05) using One-way ANOVA calculation in SPSS Statistics

Table 3: Profile of the relative percentage of total IL-6 from all IL-6-producing cells which was measured by using PE staining in a flow cytometer BD FACS Calibur, and BD CellQuest program (n=10).

<table>
<thead>
<tr>
<th>Groups</th>
<th>IL-6+ ± SD (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>38.72 ± 22.79</td>
</tr>
<tr>
<td>QUE</td>
<td>33.08 ± 15.03*</td>
</tr>
<tr>
<td>Positive control</td>
<td>3.57 ± 9.97</td>
</tr>
</tbody>
</table>

*Significantly different to the negative control group (p < 0.05) using One-way ANOVA calculation in SPSS Statistics

Inflammation in the QUE groups compared to others. The lowering inflammation sign effect was directly observed in the kidney, the most influenced organ in severe lupus (Figure 2). In this case, the cyclophosphamide cannot be a golden standard since the nephrotoxicity side effect. Therefore, the normal mice were used as the normal standard for this microscopic observation in the kidney assessment. QUE reduces the inflamed glomerulus by reducing some histopathology indicators (Figure 2). The inflammatory cells deposit in the glomerulus of QUE group seems lower than the negative control group. The mesangial tissue thickness did not decrease, but the Bowman’s capsules look wider than the negative control group. These signs are beneficial to normalize the renal function in severe lupus mice. Beside glomerulus,
Indriyanti et al.: Foxp3 Modulation of Quercetin-3-O-rhamnoside and Its Impacts on Lupus Nephritis Mouse

![Image](https://example.com/image)

**Figure 2:** The histopathological observation of the negative control group (a) (n=10), QUE (b) (n=10), and normal control group (c) (n=3) by facilitating of microscope Nikon Eclipse CI at a magnitude of 400x. The samples were prepared into 4-6 μm slides with HE staining. The ruler indicates 10 μm in length. The pictures represent all mice of each group. The highlighted parts: blue circle (glomerulus), yellow (tubules), black (proteinaceous cast), red (epithelial cells of tubules), green (inflammatory cells deposited in glomerulus), black arrow (glomerular basement membrane), green arrow (mesangium).

The next observation was tubules. Tubules are part of the kidney which can recover from damages. Tubulus in the QUE group has undamaged nuclei and has the regular appearance. The tissue condition around the glomerulus and tubules of QUE group still look unstructured compared to standard (Figure 2c). Furthermore, this detailed assessment was verified by using a semi-quantitative evaluation. The semi-quantitative assessment was done by following Moron’s method (2016) which focuses on the damage signs of glomeruli in 10 microscope observation fields. According to the assessment, we obtain the data of the change of kidney pathology severity caused by QUE (Table 4). Glomerulus inflammation decreased significantly (p<0.05) in QUE group. The percentage of damaged glomeruli (>3) is about 1.8 compared to the negative control group. This result confirms the detailed assessment and the IL-6 analysis results. At last, the anti-inflammatory effect of QUE was proven to reduce the severity of inflammation sign in lupus nephritis mice.

**DISCUSSION**

Quercetin-3-O- rhamnoside (QUE) have a better absorption profile and solubility on the gastrointestinal tract than its aglycone, quercetin. Quercetin has proven to maintain rheumatoid arthritis in a rat model. In this research, we challenged the QUE to treat a severe lupus nephritis mouse model and then we measured the biomarkers of T cell dependent pathway of lupus pathogenesis. At the first biomarker, we found an inspiring result in the T-reg marker of CD4+CD25+ T cells and FOXP3 T cells. It increased drastically after receiving QUE for three weeks (Figure 1 and Table 1). T-reg profound decreased in severe lupus condition, both in lupus patient and lupus mice significantly. The low number and low activity of T-reg impact on the disorganized T cell regulations which result in the high number of autoreactive T cells. Therefore, the auto-reactive T cells attack the healthy cell since the abnormal recognizing of "self". The genetic factors might be a cause of this disorder, but there are a lot of factors that also might be contributed in. The factors include molecular mimicry, genetics, and epigenetics. In the previously research, the relative percentage of T-reg FOXP3 in mice was lower than normal. The very low T-reg cannot eliminate the high number of autoreactive T-cell formed in the body, so the glomerulonephritis severity signs increased rapidly. After the period of QUE administration, the fact of QUE increases the T-reg number is a positive outcome which beneficially affects on lowering the auto-reactive T cells so the lupus manifestation can be handled. The glomerulonephritis occurred by the deposition of immune complex. There is a wide variety of immune complexes trapped in the glomerula. It results in inflammation, but not all the glomerula permanently damage. QUE led the inflamed glomerula to return to the occasionally form so it appears as the normal glomerula with the higher function than the inflamed ones.

In severe lupus, auto-reactive T cells lead the B cells to produce lupus-specific antibodies. The lupus-specific antibodies are named by their target, such as anti-dsDNA, anti-histone, anti-C1, etc. However, one of them is not appointed by its target, called anti-Smith (anti-Sm). Anti-Sm trigger other auto-antibodies to be produced in an abundant, and then result in the more severe lupus manifestations. In this research, QUE did not reduce the anti-Sm level significantly. The same effect also happened to the positive control group which received cyclophosphamide. It indicates that QUE mechanism is not by lowering the anti-Sm level. Further investigation is needed to find the other antibodies reduced by QUE. Nevertheless, the anti-inflammatory might be a core mechanism of the QUE efficacy on severe lupus mice. Therefore, we find that QUE reduces the total IL-6 significantly, reveal the lower cause of inflammation. The low number of pro-inflammatory cytokine will automatically reduce the anti-inflammatory cytokines. This data was confirmed by the histopathology observation which proved that the QUE reduces the glomerulus inflammation.

The effect of QUE on three steps of T cell dependent pathway of lupus pathogenesis studied can be an excellence of QUE than other compounds tested for severe lupus. At last, this study provides a sufficient data about the effect of QUE to reduce lupus manifestations in lupus mice since it increases the number of Tregs FOXP3. It is precisely useful to control the auto-reactive T cell not to damage "self" cells and tissues, and then the QUE can be developed to be a new safe and effective drug for severe lupus, especially lupus nephritis.

**CONCLUSION**

QUE has an anti-inflammatory activity which reduces the severity of lupus nephritis signs in lupus mice by initially increasing the CD4+CD25+ and FOXP3+ Tregs numbers. QUE is potential to be further developed as a safe treatment choice for lupus nephritis. However, the QUE effects on various lupus auto-antibodies need to be confirmed.
ACKNOWLEDGEMENT
We thank Faculty of Pharmacy, Mulawarman University for funding this research by a research grant number of 0734/UN.I.17.12/IT/2017 from DIPA PNRB Faculty of Pharmacy, Mulawarman University.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ABBREVIATIONS USED
ACR: American College of Rheumatology; CD: cluster of differentiation; FOXP3: Forkhead box pro 3; Kg BW: kilograms per body weight; QUE: Quercetin-3-O-rhamnoside; SLICC: Systemic Lupus Collaborating Clinics.

SUMMARY
Quercetin-3-O-rhamnoside (QUE) reduces the lupus sign in TMPD-treated lupus mice. QUE increased the relative percentage of CD4+CD25+ Treg and FOXP3+ T reg cells significantly. The high Treg number increases the immune controlling mechanism of auto-reactive cells in lupus, so the lupus manifestations can be inhibited.

REFERENCES
ACKNOWLEDGEMENT

We thank Faculty of Pharmacy, Mulawarman University for funding this research by a research grant number of 0734/UN17.12/LT/2017 from DIPA PNBP Faculty of Pharmacy, Mulawarman University.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ABBREVIATIONS USED

ACR: American College of Rheumatology; CD: cluster of differentiation; FOXP3: Forkhead box pro 3; Kg BW: kilograms per body weight; QUE: Quercetin-3-O-rhamnosoide; SLICC: Systemic Lupus Collaborating Clinics.

SUMMARY

Quercetin-3-O-rhamnosoide (QUE) reduces the lupus sign in TMPD-treated lupus mice. QUE increased the relative percentage of CD4+CD25+ Treg and FOXP3 T reg cells significantly. The high T reg number increases the immune controlling mechanism of auto-reactive cells in lupus, so the lupus manifestations can be inhibited.

REFERENCES

Editorial Board

Editor-in-Chief (2014-till date)
S. Parasuraman, M.Pharm., Ph.D.,
Editor-in-Chief, Journal of Young Pharmacist,
AIMST University, Jalan Bedong - Semeling,
08100 Bedong, Kedah Darul Aman, Malaysia.

Google scholar: https://scholar.google.co.in/citations?user=fa-XX54AAAAAJ&hl=en&oi=ao

Associate editor / Section editors
Javed Ali, M.Pharm., Ph.D.,
Dept. of Pharmaceutics,
Faculty of Pharmacy,
Jamia Hamdard,
New Delhi-110062, India

Dr. B Rajalingam, M.Pharm., Ph.D.,
Assistant Professor, Pharmacy Practice,
College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences,
Sri Ramakrishna Hospital Campus,
# 395, Sarojini Naidu Road,
Coimbatore, Tamilnadu, INDIA.

http://www.sripmscop.org/faculty_details.php?id=15

Dr. C. Soundrapandian, M.Pharm (Industrial Pharmacy) Ph.D (Pharmacy)
Professor & Head, Department of Pharmaceutics,
Himalayan Pharmacy Institute,
Majhitar, Sikkim 737136. India

Dr. A. Sureshiran MBBS, MD,
Assistant Professor of Pharmacology,
JIPMER, Pondicherry, India.

Researchgate: https://www.researchgate.net/profile/Sureshiran_Adithan2

Assistant editors
Dr. P. R. Anand Vijaya Kumar, M.Pharm., PhD.,
Department of Pharmacy Practice,
JSS college of Pharmacy,
Ooty.

Google scholar: https://scholar.google.co.in/citations?user=SU8nB31AAAAJ&hl=en

Dr. K Gowthamarajan M.Pharm., PhD.,
Department of Pharmaceutics,
JSS college of Pharmacy,
Ooty.

Chakradyra Rao Satyanarayana Uppugundur, B.Pharm., M.Sc., PhD,
Laboratoire de la fondation CANSEARCH,
Department of Pediatrics (University Hospital of Geneva),
Batiament Tulipe; 64,
Avenue De La Roseraie 1205, 
Geneve.

Researchgate: https://www.researchgate.net/profile/Chakradhara_Rao_Uppugunduri

Loop: http://loop.frontiersin.org/people/425885/overview

Arun Kumar HS, 
Department of Medicine (Cardiovascular Sciences), 
Bioscience Institute, 
University College Cork, 
College Road, Cork, Ireland.

LinkedIn: http://www.linkedin.com/in/arunkhs

Google scholar: https://scholar.google.com/citations?user=kjWW5x4AAAAJ&hl=en

Editorial Board

Dr. Raveendran R
Department of Pharmacology, 
Jawaharlal Institute of Postgraduate 
Medical Education & Research, 
Puducherry, India


Kartic Chandra Pramanik, M.Pharm., PhD, 
Pennsylvania State University 
Raleigh, NC-27613 
Mobile No. 806-316-2737

Google Scholar: https://scholar.google.com/citations?user=F_XmffsAAAAJ&hl=en

Research gate: https://www.researchgate.net/profile/Kartick_Pramanik2

Vu Dang Hoang, B.Pharm., MSc., PhD., PDF, 
Department of Analytical Chemistry and Toxicology, Hanoi College of Pharmacy. 
Home address: 304B 48A Tang Bat Ho street 
Hanoi, Vietnam


Mehdi Shafiee Ardestani, M.Pharm., Ph.D., PDF 
Department Hepatitis and AIDS Department, 
Pasteur Institute of Iran, Tehran, Iran

Google Scholar: https://scholar.google.com.my/citations?user=a_yFTF4AAAAJ&hl=en

Pulok Mukherjee, M.Pharm., Ph.D., 
Director, 
School of Natural Product Studies, 
Department of Pharmaceutical Technology, 
Jadavpur University, Kolkata.

Researchgate: https://www.researchgate.net/profile/Pulok_Mukherjee2

Dr. Emilio Russo Pharm.D., Ph.D., 
Pharmacology Chair 
Dept. of Science of Health 
University of Catanzaro, Italy

Researchgate: https://www.researchgate.net/profile/Emilio_Russo

Subhankar Chakraborty, MBBS, MD., Ph.D, 
Department of Internal Medicine 
University of Nebraska Medical Center 
Omaha, NE- 68198-2055, USA

Researchgate: https://www.researchgate.net/profile/Subhankar_Chakraborty2

Dr. Ian Cock, Ph.D., 
Biomolecular and Physical Sciences 
Griffith University, Nathan campus, 
170 Kessels Rd, Nathan, 
Queensland 4111 Australia

http://www.jyoungpharm.org/content/editorial-board
J Young Pharm

now offers the online manuscript submission and review system

Click Here

COPE
Member since 2013
JM08545

Journal of Young Pharmacists and its contents owned by InPharm are licensed under a Creative Commons Attribution-Non Commercial-No Derivs 2.5 License. Permissions beyond the scope of this license may be available at: editor@youngpharm.org


Journal of Young Pharmacists

[ISSN: Print -0975-1483, Online - 0975-1505]